{"id":"https://openalex.org/W4361819065","doi":"https://doi.org/10.1158/1078-0432.22443282","title":"Supplementary Figure 1 from Bevacizumab-Induced Alterations in Vascular Permeability and Drug Delivery: A Novel Approach to Augment Regional Chemotherapy for In-Transit Melanoma","display_name":"Supplementary Figure 1 from Bevacizumab-Induced Alterations in Vascular Permeability and Drug Delivery: A Novel Approach to Augment Regional Chemotherapy for In-Transit Melanoma","publication_year":2023,"publication_date":"2023-03-31","ids":{"openalex":"https://openalex.org/W4361819065","doi":"https://doi.org/10.1158/1078-0432.22443282"},"language":"en","primary_location":{"id":"doi:10.1158/1078-0432.22443282","doi":"https://doi.org/10.1158/1078-0432.22443282","is_oa":true,"landing_page_url":"http://dx.doi.org/10.1158/1078-0432.22443282","pdf_url":null,"source":null,"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"American Association for Cancer Research","raw_type":"posted-content"},"volume":null,"type":"supplementary-materials","indexed_in":["crossref"],"open_access":{"is_oa":true,"oa_status":"gold","oa_url":"http://dx.doi.org/10.1158/1078-0432.22443282","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5026301572","display_name":"Ryan S. Turley","orcid":"https://orcid.org/0000-0003-0842-3596","observed_orcids":["https://orcid.org/0000-0003-0842-3596"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Ryan S. Turley","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5059038104","display_name":"Andrew N. Fontanella","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Andrew N. Fontanella","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5058405024","display_name":"James C. Padussis","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"James C. Padussis","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5058720181","display_name":"Hiroaki Toshimitsu","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Hiroaki Toshimitsu","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5046851924","display_name":"Yoshihiro Tokuhisa","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Yoshihiro Tokuhisa","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5037692458","display_name":"Eugenia H. Cho","orcid":"https://orcid.org/0000-0001-5448-7895","observed_orcids":["https://orcid.org/0000-0001-5448-7895"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Eugenia H. Cho","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5033030710","display_name":"Gabi Hanna","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Gabi Hanna","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5050528758","display_name":"Georgia Marie Beasley","orcid":"https://orcid.org/0000-0001-6387-9030","observed_orcids":["https://orcid.org/0000-0001-6387-9030"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Georgia M. Beasley","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5040672041","display_name":"Christina K. Augustine","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Christina K. Augustine","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5071519548","display_name":"Mark W. Dewhirst","orcid":"https://orcid.org/0000-0003-3459-6546","observed_orcids":["https://orcid.org/0000-0003-3459-6546"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Mark W. Dewhirst","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"last","author":{"id":"https://openalex.org/A5015827608","display_name":"Douglas S. Tyler","orcid":"https://orcid.org/0000-0002-7434-846X","observed_orcids":["https://orcid.org/0000-0002-7434-846X"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Douglas S. Tyler","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]}],"institutions":[],"countries_distinct_count":0,"institutions_distinct_count":0,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":null,"issue":null,"first_page":null,"last_page":null},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10422","display_name":"Angiogenesis and VEGF in Cancer","score":0.6776999831199646,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T10422","display_name":"Angiogenesis and VEGF in Cancer","score":0.6776999831199646,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10392","display_name":"Cutaneous Melanoma Detection and Management","score":0.2337999939918518,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11533","display_name":"Melanoma and MAPK Pathways","score":0.009200000204145908,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/bevacizumab","display_name":"bevacizumab","score":1.0},{"id":"https://openalex.org/keywords/vascular-permeability","display_name":"vascular permeability","score":0.8529999852180481},{"id":"https://openalex.org/keywords/drug-delivery","display_name":"drug delivery","score":0.9039999842643738},{"id":"https://openalex.org/keywords/regional-chemotherapy","display_name":"regional chemotherapy","score":0.8029999732971191},{"id":"https://openalex.org/keywords/in-transit-melanoma","display_name":"in-transit melanoma","score":0.9860000014305115},{"id":"https://openalex.org/keywords/melanoma","display_name":"melanoma","score":0.6610000133514404},{"id":"https://openalex.org/keywords/vascular-endothelial-growth-factor","display_name":"vascular endothelial growth factor","score":0.8759999871253967},{"id":"https://openalex.org/keywords/vegf-neutralization","display_name":"VEGF neutralization","score":0.8920000195503235}],"concepts":[{"id":"https://openalex.org/C2777802072","wikidata":"https://www.wikidata.org/wiki/Q413299","display_name":"Bevacizumab","level":3,"score":0.8739776015281677},{"id":"https://openalex.org/C2779070825","wikidata":"https://www.wikidata.org/wiki/Q760434","display_name":"Augment","level":2,"score":0.8487281203269958},{"id":"https://openalex.org/C2777658100","wikidata":"https://www.wikidata.org/wiki/Q180614","display_name":"Melanoma","level":2,"score":0.5924177169799805},{"id":"https://openalex.org/C2780035454","wikidata":"https://www.wikidata.org/wiki/Q8386","display_name":"Drug","level":2,"score":0.5325291156768799},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.5242343544960022},{"id":"https://openalex.org/C113045295","wikidata":"https://www.wikidata.org/wiki/Q7916465","display_name":"Vascular permeability","level":2,"score":0.5092195272445679},{"id":"https://openalex.org/C2776694085","wikidata":"https://www.wikidata.org/wiki/Q974135","display_name":"Chemotherapy","level":2,"score":0.5020630359649658},{"id":"https://openalex.org/C2779820397","wikidata":"https://www.wikidata.org/wiki/Q1392806","display_name":"Drug delivery","level":2,"score":0.4450336694717407},{"id":"https://openalex.org/C2778022998","wikidata":"https://www.wikidata.org/wiki/Q651136","display_name":"Transit (satellite)","level":3,"score":0.4274027943611145},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.35215869545936584},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.3198292553424835},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.2506680488586426},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.24755799770355225},{"id":"https://openalex.org/C127413603","wikidata":"https://www.wikidata.org/wiki/Q11023","display_name":"Engineering","level":0,"score":0.12422055006027222},{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.10565057396888733},{"id":"https://openalex.org/C138885662","wikidata":"https://www.wikidata.org/wiki/Q5891","display_name":"Philosophy","level":0,"score":0.0},{"id":"https://openalex.org/C22212356","wikidata":"https://www.wikidata.org/wiki/Q775325","display_name":"Transport engineering","level":1,"score":0.0},{"id":"https://openalex.org/C41895202","wikidata":"https://www.wikidata.org/wiki/Q8162","display_name":"Linguistics","level":1,"score":0.0},{"id":"https://openalex.org/C539828613","wikidata":"https://www.wikidata.org/wiki/Q178512","display_name":"Public transport","level":2,"score":0.0},{"id":"https://openalex.org/C178790620","wikidata":"https://www.wikidata.org/wiki/Q11351","display_name":"Organic chemistry","level":1,"score":0.0}],"mesh":[],"locations_count":3,"locations":[{"id":"doi:10.1158/1078-0432.22443282","doi":"https://doi.org/10.1158/1078-0432.22443282","is_oa":true,"landing_page_url":"http://dx.doi.org/10.1158/1078-0432.22443282","pdf_url":null,"source":null,"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"American Association for Cancer Research","raw_type":"posted-content"},{"id":"doi:10.1158/1078-0432.22443282.v1","doi":"https://doi.org/10.1158/1078-0432.22443282.v1","is_oa":true,"landing_page_url":"https://doi.org/10.1158/1078-0432.22443282.v1","pdf_url":"https://aacr.figshare.com/articles/journal_contribution/Supplementary_Figure_1_from_Bevacizumab-Induced_Alterations_in_Vascular_Permeability_and_Drug_Delivery_A_Novel_Approach_to_Augment_Regional_Chemotherapy_for_In-Transit_Melanoma/22443282/1/files/39894243.pdf","source":null,"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"American Association for Cancer Research","raw_type":"posted-content"},{"id":"pmh:oai:figshare.com:article/22443282","doi":null,"is_oa":true,"landing_page_url":"https://figshare.com/articles/journal_contribution/Supplementary_Figure_1_from_Bevacizumab-Induced_Alterations_in_Vascular_Permeability_and_Drug_Delivery_A_Novel_Approach_to_Augment_Regional_Chemotherapy_for_In-Transit_Melanoma/22443282","pdf_url":null,"source":{"id":"https://openalex.org/S4377196282","display_name":"Figshare","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I4210132348","host_organization_name":"Figshare (United Kingdom)","host_organization_lineage":["https://openalex.org/I4210132348"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"","raw_type":"Text"}],"best_oa_location":{"id":"doi:10.1158/1078-0432.22443282","doi":"https://doi.org/10.1158/1078-0432.22443282","is_oa":true,"landing_page_url":"http://dx.doi.org/10.1158/1078-0432.22443282","pdf_url":null,"source":null,"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"American Association for Cancer Research","raw_type":"posted-content"},"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being","score":0.9537000060081482}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":true,"grobid_xml":true},"content_urls":{"pdf":"https://content.openalex.org/works/W4361819065.pdf","grobid_xml":"https://content.openalex.org/works/W4361819065.grobid-xml"},"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W4361819377","https://openalex.org/W2161261098","https://openalex.org/W2132416992","https://openalex.org/W3106761991","https://openalex.org/W2089325713","https://openalex.org/W4251733561","https://openalex.org/W2325186909","https://openalex.org/W2590539586","https://openalex.org/W2036943169","https://openalex.org/W2065660815"],"abstract_inverted_index":{"PDF":[0],"file,":[1],"126KB,":[2],"Human":[3],"melanoma":[4],"cells":[5],"secrete":[6],"VEGF":[7],"which":[8],"is":[9],"effectively":[10],"neutralized":[11],"by":[12],"bevacizumab.":[13]},"counts_by_year":[],"updated_date":"2026-11-04T10:54:05.112534","created_date":"2023-04-05T00:00:00"}